Agency for Healthcare Research and Quality. Five major steps to intervention (The "5 A's"). https://www.ahrq.gov/prevention/guidelines/tobacco/5steps.html. Accessed June 4, 2020.
Bellosta S, Corsini A. Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf. 2018;17:25-37.
Cortés-Beningola A, Fitzimons D, Pelliccia A, et al. Planning secondary prevention: Room for improvement. Eur J Prevent Cardiol. 2017;24:22-28.
Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696.
Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.
De Vries FM, Denig P, Pouwels KB, et al. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs. 2012;72:2365-2373.
Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary. J Am Coll Cardiol. 2017;69:e71-e126.
Gnatiuc L, Herrington WG, Halsey J, et al. Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies. Lancet Diabetes Endocrinol. 2018;6:538-546.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary. Circulation. 2019;139:e1082-e1143.
Mohler ER. Screening for peripheral artery disease. Circulation. 2012;126:e111-e112.
Moore JX, Chaudhary N, Akinyemiju T, et al. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, National Health and Nutrition Examination Survey, 1988–2012. Prev Chronic Dis. 2017;14:160287.
Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39:e38-e81.
Odawara M, Yamazaki T, Kishimoto J, et al. Effect of pitavastatin on the incidence of diabetes in Japanese individuals with impaired gluocse tolerance. Diabetologia. 2013;56(suppl 1):128.
Pharmacist's Letter/Prescriber's Letter. Clinically significant statin drug interactions. 2016; PL Detail-Document 280606:1-7.
Rosenson RS, Baker SK, Jacobson TA, et al. The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58–S71.
Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735-742.
Sever PS, Poulter NR, Dahlöf Björn, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care. 2005;28:1151-1157.
Taguchi I, Iimuro S, Iwata H, et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD). Circulation. 2018;137:1997-2009.
Vallejo-Vaz A, Seshasai SRK, Kurogi K, et al. Effect of pitavastatin on glucose, HbA1c, and incident diabetes: a meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis. 2015;241:409-418.
Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics – 2020 update. Circulation. 2020;141:e139-e596.
Wong ND, Zhao Y, Patel R, et al. Cardiovascular Risk factor targets and cardiovascular disease event risk in diabetes: a pooling project of the atherosclerosis risk in communities study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study. Diabetes Care. 2016;39:668-676.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Lynne T. Braun, PhD, CNP, FAHA, FPCNA, FAANP, FNLA, FAAN

Professor Emerita
Rush University
Nurse Practitioner
Rush University Medical Center
Consultant
Rush Heart Center for Women
Chicago, Illinois

Disclosures

Disclosure: Lynne T. Braun, PhD, CNP, FAHA, FPCNA, FAANP, FNLA, FAAN, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Up-to-Date.

Elizabeth J. Jackson, MSN, ACNS-BC, FNLA Diplomate

Clinical Nurse and Lipid Specialist
Accreditation Council of Clinical Lipidology
Cardio Texas PLLC
St. David's Medical Center
Austin, Texas

Disclosures

Disclosure: Elizabeth J. Jackson, MSN, ACNS-BC, FNLA Diplomate, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Janssen
Served as a speaker or a member of a speakers bureau for: Amarin; Esperion; Sanofi/Regeneron

Editors

Joy P. Marko, MS, APN-C, CCMEP

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Joy P. Marko, MS, APN-C, CCMEP, has disclosed no relevant financial relationships

Asha P. Gupta, PharmD, RPh

Senior Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Asha P. Gupta, PharmD, RPh has disclosed no relevant financial relationships.

CE Reviewer / Nurse Planner

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

CE

Statins and Diabetes Revisited

Authors: Lynne T. Braun, PhD, CNP; Elizabeth J. Jackson, MSN, ACNS-BC
CE Released: 6/18/2020
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 6/18/2021, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for cardiologists, primary care physicians, diabetologists & endocrinologists, nurse practitioners and nurses.

The goal of this activity is to increase knowledge about statin selection and dose optimization in the setting of new-onset diabetes mellitus (NODM) and to gain more confidence in optimizing lipid management in complex patients.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Statin selection and dose optimization in the setting of NODM
Have greater competence related to
- Use of effective lipid-lowering strategies in complex patients to improve lipid management

Disclosures

Faculty

Lynne T. Braun, PhD, CNP, FAHA, FPCNA, FAANP, FNLA, FAAN

Professor Emerita
Rush University
Nurse Practitioner
Rush University Medical Center
Consultant
Rush Heart Center for Women
Chicago, Illinois

Disclosures

Disclosure: Lynne T. Braun, PhD, CNP, FAHA, FPCNA, FAANP, FNLA, FAAN, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Up-to-Date.

Elizabeth J. Jackson, MSN, ACNS-BC, FNLA Diplomate

Clinical Nurse and Lipid Specialist
Accreditation Council of Clinical Lipidology
Cardio Texas PLLC
St. David's Medical Center
Austin, Texas

Disclosures

Disclosure: Elizabeth J. Jackson, MSN, ACNS-BC, FNLA Diplomate, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Janssen
Served as a speaker or a member of a speakers bureau for: Amarin; Esperion; Sanofi/Regeneron

Editors

Joy P. Marko, MS, APN-C, CCMEP

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Joy P. Marko, MS, APN-C, CCMEP, has disclosed no relevant financial relationships

Asha P. Gupta, PharmD, RPh

Senior Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Asha P. Gupta, PharmD, RPh has disclosed no relevant financial relationships.

CE Reviewer / Nurse Planner

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Nurses

Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

Statin Selection in Patients at Risk

From Medscape Education Cardiology

Statins and Diabetes Revisited

Authors: Lynne T. Braun, PhD, CNP; Elizabeth J. Jackson, MSN, ACNS-BCFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CE Released: 6/18/2020

Valid for credit through: 6/18/2021, 11:59 PM EST

processing....

CE Information Download Slides

Activity Transcript

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Lynne T. Braun, PhD, CNP, FAHA, FPCNA, FAANP, FNLA, FAAN

Elizabeth J. Jackson, MSN, ACNS-BC, FNLA Diplomate

Editors

Joy P. Marko, MS, APN-C, CCMEP

Asha P. Gupta, PharmD, RPh

CE Reviewer / Nurse Planner

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

CE

Statins and Diabetes Revisited

Target Audience and Goal Statement

Disclosures

Faculty

Lynne T. Braun, PhD, CNP, FAHA, FPCNA, FAANP, FNLA, FAAN

Elizabeth J. Jackson, MSN, ACNS-BC, FNLA Diplomate

Editors

Joy P. Marko, MS, APN-C, CCMEP

Asha P. Gupta, PharmD, RPh

CE Reviewer / Nurse Planner

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Accreditation Statements

For Nurses

Instructions for Participation and Credit

Statins and Diabetes Revisited